Literature DB >> 21148033

NLRC5 deficiency does not influence cytokine induction by virus and bacteria infections.

Himanshu Kumar1, Surya Pandey, Jian Zou, Yutaro Kumagai, Ken Takahashi, Shizuo Akira, Taro Kawai.   

Abstract

Nucleotide-binding domain and leucine rich repeat containing gene family receptors (NLRs) are cytosolic proteins that respond to a variety of pathogen and host components to induce inflammatory cytokines. NLRC5 is a recently identified member of the NLR family that has been implicated in positive and negative regulation of antiviral innate immune responses. To clarify whether NLRC5 controls antiviral innate immunity in vivo, we generated NLRC5-deficient mice. Macrophages and dendritic cells derived from NLRC5-deficient mice induced relatively normal levels of IFN-β, IL-6, and TNF-α after treatment with RNA viruses, DNA viruses, and bacteria. The serum cytokine levels after polyinosinic-polycytidylic acid infection were also comparable between control and NLRC5-deficient mice. NLRC5 overexpression promoted IL-1β production via caspase-1, suggesting that NLRC5 constitutes an inflammasome. However, there was no reduction of IL-1β in NLRC5-deficient cells in response to known inflammasome activators, suggesting that NLRC5 controls IL-1β production through an unidentified pathway. These findings indicate that NLRC5 is dispensable for cytokine induction in virus and bacterial infections under physiologic conditions.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21148033     DOI: 10.4049/jimmunol.1002094

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  55 in total

1.  NLRC5 regulates MHC class I antigen presentation in host defense against intracellular pathogens.

Authors:  Yikun Yao; Yalong Wang; Fuxiang Chen; Yin Huang; Shu Zhu; Qibin Leng; Hongyan Wang; Yufang Shi; Youcun Qian
Journal:  Cell Res       Date:  2012-04-10       Impact factor: 25.617

Review 2.  Cross-regulation between the IL-1β/IL-18 processing inflammasome and other inflammatory cytokines.

Authors:  Brianne R Barker; Debra J Taxman; Jenny P-Y Ting
Journal:  Curr Opin Immunol       Date:  2011-08-10       Impact factor: 7.486

Review 3.  Emerging significance of NLRs in inflammatory bowel disease.

Authors:  Beckley K Davis; Casandra Philipson; Raquel Hontecillas; Kristin Eden; Josep Bassaganya-Riera; Irving C Allen
Journal:  Inflamm Bowel Dis       Date:  2014-12       Impact factor: 5.325

Review 4.  Initiation and perpetuation of NLRP3 inflammasome activation and assembly.

Authors:  Eric I Elliott; Fayyaz S Sutterwala
Journal:  Immunol Rev       Date:  2015-05       Impact factor: 12.988

5.  NLRC5: a NOD-like receptor protein with many faces in immune regulation.

Authors:  Yue Zhao; Feng Shao
Journal:  Cell Res       Date:  2012-05-22       Impact factor: 25.617

6.  Deficiency of the NOD-Like Receptor NLRC5 Results in Decreased CD8+ T Cell Function and Impaired Viral Clearance.

Authors:  Christopher R Lupfer; Kate L Stokes; Teneema Kuriakose; Thirumala-Devi Kanneganti
Journal:  J Virol       Date:  2017-08-10       Impact factor: 5.103

Review 7.  Molecular mechanisms of inflammasome activation during microbial infections.

Authors:  Petr Broz; Denise M Monack
Journal:  Immunol Rev       Date:  2011-09       Impact factor: 12.988

Review 8.  Mechanisms and pathways of innate immune activation and regulation in health and cancer.

Authors:  Jun Cui; Yongjun Chen; Helen Y Wang; Rong-Fu Wang
Journal:  Hum Vaccin Immunother       Date:  2014       Impact factor: 3.452

Review 9.  Class I transactivator, NLRC5: a central player in the MHC class I pathway and cancer immune surveillance.

Authors:  Saptha Vijayan; Tabasum Sidiq; Suhail Yousuf; Peter J van den Elsen; Koichi S Kobayashi
Journal:  Immunogenetics       Date:  2019-01-31       Impact factor: 2.846

Review 10.  NLRP7 and related inflammasome activating pattern recognition receptors and their function in host defense and disease.

Authors:  Alexander D Radian; Lucia de Almeida; Andrea Dorfleutner; Christian Stehlik
Journal:  Microbes Infect       Date:  2013-04-22       Impact factor: 2.700

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.